This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA

JAMA. 2001;285:34.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

The FDA has approved Trizivir (Glaxo Wellcome, Research Triangle Park, NC), alone or in combination with other antiretroviral agents, for the treatment of HIV-1 infection in adults and adolescents. Trizivir is a combination of three synthetic nucleoside analogs previously approved by the FDA: abacavir sulfate (Ziagen), lamivudine (Epivir), and zidovudine (Retrovir). One Trizivir tablet is bioequivalent to one tablet each of Ziagen (300 mg), Epivir (150 mg), and Retrovir (300 mg). As a fixed-dosage tablet, Trizivir is not recommended for treatment of patients who weigh less than 90 lb.

The indication for Trizivir is based on analyses of surrogate markers in controlled studies with abacavir of up to 24 weeks' duration. Trizivir itself has also been studied in smaller studies. Currently, there are no results from controlled trials evaluating long-term suppression of HIV RNA or disease progression with abacavir or trizivir.

Health care practitioners and patients should be aware that . . . [Full Text of this Article]